Table 7

Multivariate analysis of relapse-free survival in the combined 602-patient cohort

Factor

Hazard ratio (95% CI)

P

Tumor grade (3 versus 1 or 2)

1.18 (0.88–1.57)

0.3

Tumor size, cm

0.02

>2–5 versus 0–2

1.49 (1.10–2.00)

0.009

>5 versus 0–2

1.63 (1.09–2.46)

0.02

Lymphovascular invasion

1.13 (0.78–1.65)

0.5

Percentage of positive nodes

0.001

>50–99 versus 0–50

1.25 (0.94–1.66)

0.1

100 versus 0–50

1.90 (1.35–2.71)

0.003

ER

0.91 (0.63–1.32)

0.6

PR

0.72 (0.54–0.96)

0.02

HER2

1.22 (0.89–1.66)

0.2

EGFR

1.13 (0.71–1.80)

0.6

Ki-67

1.39 (1.05–1.84)

0.02

p53

1.00 (0.74–1.35)

0.99

CA IX

1.58 (1.12–2.22)

0.008

CK5/6

0.98 (0.61–1.57)

0.9

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; EGFR, human epidermal growth factor receptor 1; CA IX, carbonic anhydrase IX, CK5/6, cytokeratin 5/6; CI, confidence interval.

Crabb et al. Breast Cancer Research 2008 10:R6   doi:10.1186/bcr1847